Biagio Ricciuti, Carlo Genova, Maria Bassanelli, Andrea De Giglio, Marta Brambilla, Giulio Metro, Sara Baglivo, Maria Giovanna Dal Bello, Anna Ceribelli, Francesco Grossi, Rita Chiari,
Introduction Treatment with immune checkpoint inhibitors beyond progression is associated with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether this association exists for patients with non–small-cell lung cancer (NSCLC) is currently still unclear. Patients and Methods We performed a multi-institutional retrospective study based on landmark and multivariable analyses to evaluate the safety and efficacy of treatment with nivolumab beyond Response Evaluation Criteria ...
Tópico(s): Lung Cancer Treatments and Mutations
2019 - Elsevier BV | Clinical Lung Cancer
Biagio Ricciuti, Carlo Genova, Andrea De Giglio, Maria Bassanelli, Maria Giovanna Dal Bello, Giulio Metro, Marta Brambilla, Sara Baglivo, Francesco Grossi, Rita Chiari,
Tópico(s): CAR-T cell therapy research
2018 - Springer Science+Business Media | Journal of Cancer Research and Clinical Oncology
Giuseppe Luigi Banna, Marcello Tiseo, Diego Cortinovis, Francesco Facchinetti, Joachim G.J.V. Aerts, Cinzia Baldessari, Raffaele Giusti, Emilio Bria, Francesco Grossi, Rossana Berardi, Alessandro Morabito, Annamaria Catino, Carlo Genova, Francesca Mazzoni, Alain Gelibter, Francesca Rastelli, Marianna Macerelli, Rita Chiari, Stefania Gori, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Erika Rijavec, Federica Bertolini, Federico Cappuzzo, Alessandro De Toma, Alex Friedlaender, Giulio Metro, Maria Vittoria Pensieri, Giampiero Porzio, Corrado Ficorella, David J. Pinato, Alessio Cortellini, Alfredo Addeo,
Abstract Background Patients with programmed cell death‐ligand 1 (PD‐L1) ≥50% metastatic non‐small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first‐line immunotherapy have heterogeneous clinical assessment and outcomes. Methods To explore the role of immune‐inflammatory surrogates by the validated lung immuno‐oncology prognostic score (LIPS) score, including the neutrophil‐to‐lymphocyte ratio (NLR) and the pretreatment use of steroids, alongside other prognostic variables. ...
Tópico(s): Lung Cancer Research Studies
2021 - Wiley | Thoracic Cancer
Biagio Ricciuti, Carlo Genova, Andrea De Giglio, Marta Brambilla, Maria Bassanelli, Maria Giovanna Dal Bello, Sara Baglivo, Giulio Metro, Francesco Grossi, Rita Chiari,
Anti PD1 and anti PD-L1 monoclonal antibodies represent the standard of care for platinum-pretreated advanced non-small cell lung cancer (NSCLC) patients, having shown to prolong survival compared to chemotherapy in second-line setting in phase III clinical trials. Patients treated with these drugs not infrequently experience immune-related adverse events (irAEs), which we hypothesize might reflect antitumor response. In this study we investigated whether the development of irAEs was associated with ...
Tópico(s): Economic and Financial Impacts of Cancer
2018 - Elsevier BV | Journal of Thoracic Oncology
Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, M. D’Arcangelo, Andrea Sbrana, Marco Russano, Laura Bonanno, Raffaele Giusti, Giulio Metro, Federica Bertolini, Salvatore Grisanti, Annamaria Carta, Fabiana Letizia Cecere, Michele Montrone, Giacomo Massa, Fabiana Perrone, Francesca Simionato, Giorgia Guaitoli, Vieri Scotti, Carlo Genova, Antonio Lugini, Lucia Bonomi, Ilaria Attili, Filippo de Marinis,
The selective RET-inhibitor pralsetinib has shown therapeutic activity in early clinical trials in patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) gene fusions. To date, the real-world efficacy of pralsetinib in this population is unknown.A retrospective efficacy and safety analysis was performed on data from patients with RET-fusion positive NSCLC enrolled in the pralsetinib Italian expanded access program between July 2019 and October 2021.Overall, ...
Tópico(s): Cholangiocarcinoma and Gallbladder Cancer Studies
2022 - Elsevier BV | Lung Cancer
Andrea De Giglio, Giuseppe Lamberti, Francesco Facchinetti, Carlo Genova, Elisa Andrini, Maria Giovanna Dal Bello, Marcello Tiseo, Giulio Metro, Rita Chiari, Biagio Ricciuti,
Background ROS1 rearrangements define a subset of non–small-cell lung cancers (NSCLCs) that are susceptible to therapeutic ROS1 kinase inhibition. Despite the fact that most patients initially respond to the first-generation ROS1 tyrosine kinase inhibitor (TKI) crizotinib, relapse invariably occurs, and therapeutic options upon disease progression are limited. Patients and Methods We conducted a multicenter study of patients with ROS1-rearranged NSCLC who progressed on ROS1 TKIs and examined the clinical ...
Tópico(s): Colorectal Cancer Treatments and Studies
2020 - Elsevier BV | Clinical Lung Cancer
Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Daniele Santini, Sebastiano Buti, Olga Nigro, Luca Cantini, Massimo Di Maïo, Joachim G.J.V. Aerts, Emilio Bria, Federica Bertolini, Miriam Grazia Ferrara, Michele Ghidini, Francesco Grossi, Annalisa Guida, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Lorenzo Antonuzzo, Alain Gelibter, Paolo Marchetti, Rita Chiari, Marianna Macerelli, Francesca Rastelli, Luigi Della Gravara, Stefania Gori, Alessandro Tuzi, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Pecci, Federica Zoratto, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Giulio Metro, Gian Paolo Spinelli, Giuseppe Luigi Banna, Alex Friedlaender, Alfredo Addeo, Corrado Ficorella, Giampiero Porzio, Marcello Tiseo, Marco Russano, Alessandro Russo, David J. Pinato,
Abstract Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, ...
Tópico(s): Lung Cancer Treatments and Mutations
2022 - BioMed Central | Journal of Hematology & Oncology
Produção Nacional
Revisado por pares
Rodrigo do Vale Ferreira, Marinês Bastianel, Fernando Alves de Azevedo, José Dagoberto De Negri,
... lise de determinação de seus parâmetros fÃsicos e quÃmicos e a consequente distinção entre eles. Os resultados mostraram grande variação nos materiais estudados quanto ao desenvolvimento da copa, sendo que os cultivares Allen Eureka e Genova apresentaram menor porte, com potencial para plantios adensados. Quanto à qualidade de fruto os genótipos Meyer e Genova se destacaram ...
Tópico(s): Pineapple and bromelain studies
2018 - | Citrus Research & Technology
Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna, Federico Cappuzzo, Joachim G.J.V. Aerts, Fausto Barbieri, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria Rita Migliorino, Domenico Galetta, Francesco Passiglia, Daniele Santini, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Erika Rijavec, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Fabrizio Citarella, Marco Russano, Mariangela Torniai, Luca Cantini, Giada Targato, Vincenzo Sforza, Olga Nigro, Miriam Grazia Ferrara, Ettore D’Argento, Sebastiano Buti, Paola Bordi, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A. Belderbos, Paolo Bironzo, Simona Carnio, Serena Ricciardi, Alessio Grieco, Alessandro De Toma, Claudia Proto, Alex Friedlaender, Ornella Cantale, Biagio Ricciuti, Alfredo Addeo, Giulio Metro, Corrado Ficorella, Giampiero Porzio,
Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naïve NSCLC and a PD-L1 expression of ≥ 50%. One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI ...
Tópico(s): Colorectal Cancer Treatments and Studies
2020 - Springer Science+Business Media | Cancer Immunology Immunotherapy
Alessio Cortellini, Katia Cannita, Marcello Tiseo, Diego Cortinovis, Joachim G.J.V. Aerts, Cinzia Baldessari, Raffaele Giusti, Miriam Grazia Ferrara, Ettore D’Argento, Francesco Grossi, Annalisa Guida, Rossana Berardi, Alessandro Morabito, Carlo Genova, Lorenzo Antonuzzo, Francesca Mazzoni, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Giada Targato, Francesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Sergio Bracarda, Fabrizio Citarella, Marco Russano, Luca Cantini, Olga Nigro, Sebastiano Buti, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria Rita Migliorino, Salvatore Natalizio, Simona Carnio, Marco De Filippis, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Massimo Di Maïo, Giuseppe Luigi Banna, Alex Friedlaender, Alfredo Addeo, David J. Pinato, Corrado Ficorella, Giampiero Porzio,
Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression ≥50%.We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression ≥ 50% treated with first-line pembrolizumab monotherapy.Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15. ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2021 - Elsevier BV | European Journal of Cancer
Produção Nacional
Revisado por pares
Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Alessandro Leonetti, Diego Cortinovis, Joachim G.J.V. Aerts, Giorgia Guaitoli, Fausto Barbieri, Raffaele Giusti, Miriam Grazia Ferrara, Emilio Bria, Ettore D’Argento, Francesco Grossi, Erika Rijavec, Annalisa Guida, Rossana Berardi, Mariangela Torniai, Vincenzo Sforza, Carlo Genova, Francesca Mazzoni, Marina Chiara Garassino, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Marco Siringo, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Luigi Della Gravara, Alessandro Inno, De Tursi Michele, Antonino Grassadonia, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Daniele Santini, Fabrizio Citarella, Marco Russano, Luca Cantini, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Paolo Bironzo, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe Luigi Banna, Alex Friedlaender, Alfredo Addeo, Katia Cannita, Corrado Ficorella, Giampiero Porzio, David J. Pinato,
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative is matter of debate. Methods We present the outcomes analysis according to concomitant baseline medications (prior to ICI initiation) with putative ...
Tópico(s): Lung Cancer Treatments and Mutations
2021 - BMJ | Journal for ImmunoTherapy of Cancer
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Sergio Bracarda, Massimo Di Maïo, Raffaele Giusti, Olga Nigro, Diego Cortinovis, Joachim G.J.V. Aerts, Giorgia Guaitoli, Fausto Barbieri, Miriam Grazia Ferrara, Emilio Bria, Francesco Grossi, Claudia Bareggi, Rossana Berardi, Mariangela Torniai, Luca Cantini, Vincenzo Sforza, Carlo Genova, Rita Chiari, Danilo Rocco, Luigi Della Gravara, Stefania Gori, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Fabrizio Citarella, Marco Russano, Francesca Mazzoni, Marina Chiara Garassino, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Marco Siringo, Alessandro Follador, Renato Bisonni, Alessandro Tuzi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria Rita Migliorino, Fabrizio Tabbò, Emanuela Olmetto, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe Luigi Banna, Alfredo Addeo, Alex Friedlaender, Katia Cannita, Giampiero Porzio, Corrado Ficorella, Luca Carmisciano, David J. Pinato, Giulia Mazzaschi, Marcello Tiseo, Alessio Cortellini,
Background We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a drug-based prognostic score to be calculated before immunotherapy initiation in patients with advanced solid tumours. This 'drug score' was calculated assigning score 1 for each between proton-pump inhibitor and antibiotic administration until a month before cancer therapy ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2021 - Elsevier BV | European Journal of Cancer
Giuseppe Luigi Banna, Alessio Cortellini, Diego Cortinovis, Marcello Tiseo, Joachim G.J.V. Aerts, Fausto Barbieri, Raffaele Giusti, Emilio Bria, Francesco Grossi, Pamela Pizzutilo, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alain Gelibter, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Michele Montrone, Fabrizio Citarella, Rosanna De Marco, Luca Cantini, Olga Nigro, Ettore D’Argento, Sebastiano Buti, Gabriele Minuti, Lorenza Landi, Giorgia Guaitoli, Giuseppe Lo Russo, Alessandro De Toma, Clelia Donisi, Alex Friedlaender, Andrea De Giglio, Giulio Metro, Giampiero Porzio, Corrado Ficorella, Alfredo Addeo,
To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated with first-line immunotherapy.Baseline clinical prognostic factors, the neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour cell expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis of 784 patients divided between statistically powered training (n = 201) and validation (n = 583) cohorts. Cut-offs were explored ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2021 - Elsevier BV | ESMO Open
Emanuela Olmetto, Carlos A. Mattioli, Saverio Caini, Marco Del Riccio, Marco Banini, A. Sbrana, Cristina Zannori, Giovanna Finocchiaro, Elisa Roca, Giulio Metro, Marianna Macerelli, Alessandro Russo, Angelo Delmonte, Carlo Genova, Diego Cortinovis, M. D’Arcangelo, Marco Perna, Alessio Bruni, Lorenzo Livi, Vieri Scotti,
Different blood markers have been investigated as prognostic indexes in NSCLC. Neutrality trial wants to analyze how NLR (Neutrophil to Lymphocytes ratio) and SII (Systemic Inflammatory Index - NLR x platelets) impact on outcomes of patients treated in accordance with Pacific regimen. In the last years new indexes such as the dNLR (neutrophil to leukocytes - neutrophil ratio) and the LIPI (Lung Immune Prognostic Index) have been validated in advanced NSCLC and are considered in the present analysis. Patients ...
Tópico(s): Cancer Diagnosis and Treatment
2024 - Elsevier BV | ESMO Open
R. Bozzo, R. Genova, Fabio Ballini,
... cases, tunnels have been built to accommodate full metro trains if desired (Stuttgart, Frankfurt a/M, Bochum, ...
Tópico(s): Mobile Agent-Based Network Management
2010 - WIT Press | WIT transactions on the built environment
Produção Nacional
Revisado por pares
Giuseppe Luigi Banna, Alessio Cortellini, Diego Cortinovis, Marcello Tiseo, J.G.J.V. Aerts, Fausto Barbieri, Raffaele Giusti, Emilio Bria, Francesco Grossi, Pamela Pizzutilo, R. Berardi, Antonino Morabito, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alain Gelibter, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Pietro Di Marino, Gelsomina Mansueto, Federica Zoratto, Marco Filetti, Michele Montrone, Fabrizio Citarella, Ranieri Vito Marco, Luca Cantini, Olga Nigro, Ettore D’Argento, Sebastiano Buti, Gabriele Minuti, Lorenza Landi, Giorgia Guaitoli, Giuseppe Lo Russo, Alessandro De Toma, Clelia Donisi, Alex Friedlaender, Andrea De Giglio, Giulio Metro, Giampiero Porzio, Corrado Ficorella, Alfredo Addeo,
Tópico(s): Lung Cancer Diagnosis and Treatment
2021 - Elsevier BV | ESMO Open
Arsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Giulio Metro, Giulia Galli, Francesco Agustoni, Carminia Maria Della Corte, Andrea Spagnoletti, Claudia Giani, Roberto Ferrara, Claudia Proto, Marta Brambilla, Andra Diana Dumitrascu, Alessandro Inno, Diego Signorelli, Elio Gregory Pizzutilo, Matteo Brighenti, Federica Biello, Chiara Bennati, Luca Toschi, Marco Russano, Alessio Cortellini, Chiara Catania, Federica Bertolini, Rossana Berardi, Luca Cantini, Federica Pecci, Marianna Macerelli, Rita Emili, Claudia Bareggi, Francesco Verderame, Antonio Lugini, Salvatore Pisconti, Federica Buzzacchino, Michele Aieta, Alfredo Tartarone, Gianpaolo Spinelli, Emanuele Vita, Salvatore Grisanti, Francesco Trovò, Pietro Auletta, Daniele Lorenzini, Luca Agnelli, Sabina Sangaletti, Francesca Mazzoni, Giuseppina Calareso, Margherita Ruggirello, Gabriella Greco, Raffaella Vigorito, Mario Occhipinti, Sara Manglaviti, Teresa Beninato, Rita Leporati, Paolo Ambrosini, Roberta Serino, Cecilia Silvestri, Emanuela Zito, Alessandra Chiara Laura Pedrocchi, Vanja Mišković, Filippo de Braud, Giancarlo Pruneri, Giuseppe Lo Russo, Carlo Genova, Andrea Vingiani,
Introduction Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been aimed at indentifying biomarkers able to predict benefit from these therapies and create a prediction model of response, despite this there is a lack of information to help clinicians in the choice of therapy for lung cancer patients ...
Tópico(s): Radiomics and Machine Learning in Medical Imaging
2023 - Elsevier BV | Clinical Lung Cancer
Produção Nacional
Revisado por pares
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J. Pinato, Jarushka Naidoo, Artur Katz, Matthew J. Loza, Joel W. Neal, Carlo Genova, Scott Gettinger, So Yeon Kim, Ritujith Jayakrishnan, Talal El Zarif, Marco Russano, Federica Pecci, Alessandro Di Federico, Mark M. Awad, Joao V. Alessi, Michele Montrone, Dwight H. Owen, Diego Signorelli, Mary J. Fidler, Mingjia Li, Andrea Camerini, Andrea De Giglio, Lauren Young, Bruno Vincenzi, Giulio Metro, Francesco Passiglia, Sai Yendamuri, Annalisa Guida, Michele Ghidini, Nichola Awosika, Andrea Napolitano, Claudia A M Fulgenzi, Salvatore Grisanti, Francesco Grossi, Armida D’Incecco, Eleni Josephides, Mieke Van Hemelrijck, Alessandro Russo, Alain Gelibter, Gianpaolo Spinelli, Monica Verrico, Bartłomiej Tomasik, Raffaele Giusti, Thomas Newsom-Davis, Emilio Bria, Martin Sebastian, Maximilian Rost, Martin Förster, Uma Mukherjee, Lorenza Landi, Francesca Mazzoni, Avinash Aujayeb, Madeleine Dupont, Alessandra Curioni‐Fontecedro, Rita Chiari, Francesco Pantano, Alessandro Morabito, Alessandro Leonetti, Alex Friedlaender, Alfredo Addeo, Federica Zoratto, Michele De Tursi, Luca Cantini, Elisa Roca, Giannis Mountzios, Luigi Della Gravara, Sukumar Kalvapudi, Alessandro Inno, Paolo Bironzo, Rita Barros, David O’Reilly, Jack Bell, Eleni Karapanagiotou, Isabelle Monnet, Javier Baena Preysler, Marianna Macerelli, Margarita Majem, Francesco Agustoni, Diego Cortinovis, Giuseppe Tonini, Gabriele Minuti, Chiara Bennati, Laura Mezquita, Teresa Gorría, Alberto Servetto, Teresa Beninato, Giuseppe Lo Russo, Jacobo Rogado, Laura Moliner, Federica Biello, Frank Aboubakar Nana, Anne‐Marie C. Dingemans, Joachim G.J.V. Aerts, Roberto Ferrara, Valter Torri, Taher Abu Hejleh, Kazuki Takada, Abdul Rafeh Naqash, Marina Chiara Garassino, Solange Peters, Heather Wakelee, Talal El Zarif, Biagio Ricciuti,
Tópico(s): Esophageal Cancer Research and Treatment
2025 - BMJ | Journal for ImmunoTherapy of Cancer